The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2019 | Onvansertib with cytarabine or decitabine for R/R AML
Amer Zeidan, MBBS, MHS, Yale University and Yale Cancer Center, New Haven, CT, discusses the ongoing phase 1b dose-escalation trial (NCT03303339) evaluating the safety, efficacy and correlative analyses of onvansertib, a PLK-1 inhibitor, in combination with either low-dose cytarabine or decitabine in relapsed/refractory acute myeloid leukemia (AML). This interview took place at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.
